Higher Hb increase in RA patients RX with Sarilumab vs Adalimumab, and reduction of %pts w anemia. Not u expected since we know IL6’s role in anemia of chronic disease @RheumNow #ACR18 pic.twitter.com/Gc4RpFRmAt
— Dr. Arthur Lau (@ArthurRheum) October 22, 2018
Ongoing safety data for tofacitinib and baricitinib were presented Abst 963 and 962 for 9.5 and 6 yrs respectively. No new safety signals in either. HZ rates were similar in both. Low rates of DVT/PE shown in pic for Bari ACR18 @RheumNow pic.twitter.com/jceohUaqCK
— Janet Pope (@Janetbirdope) October 22, 2018
Check Point inhibitors and the Rheumatologist. ACR18 #RheumNow Abstract 4M039 pic.twitter.com/ddnzhTydZi
— William Shergy (@WilliamShergy) October 22, 2018